Tag Archive for: DualityBIO

biontech-trastuzumab-pamirtecanBioNTech
Clinical Trials

BioNTech reports promising Phase II data for uterine cancer ADC

Mainz‑based biotech BioNTech has presented compelling Phase II data for its compound trastuzumab pamirtecan. The antibody–drug conjugate (ADC) was evaluated in patients with advanced uterine cancer who had previously undergone multiple lines of treatment.

Read more
© BioNTech SE
partnership

German-Chinese ADC collaboration

BioNTech has entered the ADC field with an exclusive license and collaboration agreement with China’s DualityBio Ltd for two antibody-drug conjugate (ADC) assets.

Read more